Purpose: To evaluate the effectiveness of 18F-Fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) for detecting early cancer in carriers of germline TP53 mutation, the genetic defect underlying Li-Fraumeni and related syndromes, which predisposes to many forms of cancer throughout life.Patients and methods: A total of 30 adult patients from six families with germline TP53 mutations were recruited. These patients did not have a diagnosis of cancer in the 24 months preceding the study. Anomalous concentrations from whole-body 18F-FDG-PET/CT were assessed by two independent experts. Suspicious lesions were excised and subjected to pathological examination.Results: A total of 6/30 patients showed abnormal 18F-FDG-concentration. Confirmation studies revealed three cases of cancer, including one lung cancer, one ovarian cancer, and one disseminated breast cancer. Three patients had non-malignant lesions (one Bartholin’s cyst and two cases of reactive lymph nodes).Conclusion: 18F-FDG-PET/CT is effective in detecting cancer in subjects who are asymptomatic according to current screening guidelines. These results further suggest that 18F-FDG-PET/CT is an appropriate method for surveillance of cancer risk in TP53 mutation carriers.

Objective: To compare 68Ga-DOTA-DPhe1,Tyr3-octreotate (68Ga-DOTATATE) positron-emission tomography/computed tomography (PET/CT) findings with those of conventional 111In-octreotide scintigraphy in patients with neuroendocrine tumors (NETs). Materials and Methods: This was a single-center prospective study including 41 patients (25 males; mean age, 55.4 years) with biopsy-proven NETs who underwent whole-body 111In-octreotide scintigraphy and whole-body 68Ga-DOTATATE PET/CT. The patients had been referred for tumor staging (34.1%), tumor restaging (61.0%), or response evaluation (4.9%). Images were compared in a patient-by-patient analysis to identify additional lesions, and we attempted to determine the impact that discordant findings had on treatment planning. Results: Compared with 111In-octreotide scintigraphy, 68Ga-DOTATATE PET/CT revealed more lesions, the additional lesions typically being in the liver or bowel. Changes in management owing to the additional information provided by 68Ga-DOTATATE PET/CT occurred in five patients (12.2%), including intermodal changes in three (7.3%) and intramodal changes in two (4.9%). In addition, 68Ga-DOTATATE PET/CT yielded incidental findings unrelated to the primary NET in three patients (7.3%): Hürthle cell carcinoma of the thyroid, bowel non-Hodgkin lymphoma, and a suspicious breast lesion. Conclusion: We conclude that 68Ga-DOTATATE PET/CT is superior to conventional 111In-octreotide scintigraphy for the management of NETs because of its ability to determine the extent of the disease more accurately, which, in some cases, translates to changes in the treatment plan.

No abstract

Conclusion: Thus, the use of surgical removal of metastases in the liver with CRC, at one of the stages of treatment, significantly increases its effectiveness, with both solitary and multiple metastatic liver damage compared with only conservative methods.

Introduction/Background: Pulmonar thromboembolism (PTE) is characterized by obstruction of pulmonary circulation by blood clots and is commonly observed in hospitalized cancer patients. It is diagnosed using thoracic ANGIO-TC and pulmonary inhalation/perfusion (I/P) techniques by SPECT-CT3,6,7,9. The aim of this study is to analyse the performance of these two techniques in the diagnosis of PTE and to evaluate the concordance between their results patients profiles, and impact on clinical medical management. Methods: A descriptive, retrospective, quantitative, qualitative and unicentric cohort study; was carried out by analysing the ANGIO-CT and I/P tests by SPECT-CT of the population of câncer patients in a tertiary oncological institution from January 2015 to May 2018. A total of 410 tests in 363 patients were analysed. Results: Three hundred and thirty five patients underwent ANGIO-CT, 75 underwent I/P by SPECT-CT and 47 patients both.  The types of cancer that showed association with the diagnosis of PTE were lung, pancreas and brain cancers. Lung cancer showed the highest association with suspected and diagnosed PTE. Discussion: Diagnostic results and clinical managment were comparable for both SPECT-CT and ANGIO-CT. Both methods have proven to be reliable and highly accurate for the diagnosis of PTE in cancer patients. Conclusion: The SPECT-CT has shown great accuracy for the diagnosis of negative PTE and may be preferable and more indicated to rule out PTE in cancer patients due to its lower radiation, but for the diagnosis of positive PTE the chest ANGIO-TC is even more indicated.